Impact Therapeutics, founded in 2009, focuses on the discovery, development and commercialization of novel therapeutics to treat cancer and other life-threatening diseases.
Company (Alive / Active)
Spark Road, High-tech Development Zone
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)
|1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof||Feb 12, 2016||Mar 27, 2018||Patent|
|Solid pharmaceutical formulation of parp inhibitors and use thereof||Apr 01, 2016||Application|